Mode of access: Internet via World Wide Web. text file PDF
In Sight is a memoir about how a love of science and discovery drove Julia Levy, a celebrated scholar and biotech CEO, to work her way through gender bias in order to achieve academic and professional recognition. Her story traces the unconventional invention of a breakthrough drug treatment from its development from laboratory research to its application as a medical treatment for vision loss. Told from a female perspective, In Sight is a unique and personal story covering Levy's early years as a refugee, her university training in the UK and her appointment as professor at the University of British Columbia. Years spent as an academic led the author to unexpected exposure to the biotechnology industry and a chance meeting with colleagues that led to the formation of a lucrative biotechnology company, known today as QLT Incorporated The bulk of the book covers the years spent building the company, and Levy's surprising transition from chief scientific officer to CEO. In Sight is an honest description of the trials of drug development, the tensions inherent in the commercialization of health innovations, and the truly remarkable hurdles faced by women in the scientific community.
Frontmatter Contents Foreword 1 Waiting for the Other Shoe to Drop 2 Does Your Dog Always Sit in the Front Seat? 3 Where I Wanted to Be 4 Life in Bed-Sits 5 Woefully Outclassed 6 Whose Lab Do You Work in? 7 Earning My Stripes 8 Seeing the Light 9 Becoming Part of a Biotech Start-Up 10 Positioning QLT as a Photodynamic Therapy Company 11 Colleagues at American Cyanamid Come to Our Rescue 12 The Nation's Blood Supply 13 PDT Is Different from Other Cancer Drugs 14 I Was Surprised and Not at All Pleased 15 Splitting Up 16 Failure Was Never an Option 17 Nothing Can Prepare You for the Torture of ODAC 18 Taking Big Steps in Our AMD Clinical Trials 19 An Open and Respectful Relationship 20 Our Work on Age-Related Macular Degeneration Is Her Legacy 21 We at QLT Were on Pins and Needles 22 People Couldn't Stop Smiling 23 More Than a One-Trick Pony 24 Launching the Product and Hoping for No Unpleasant Surprises 25 Growing the Company 26 Time to Reflect 27 An Enormous Rush of Relief 28 A Biotech Company with a Lot of Money Is in Danger 29 I Thought These Problems Would Be Transient 30 Ongoing Headaches 31 He Felt Thoroughly Betrayed 32 Problems with Activist Shareholders 33 New Opportunity Acknowledgments About the Author Index
Description based on online resource; title from PDF title page (publisher's Web site, viewed 06. Jan 2021)